US employers pulling GLP-1 coverage in 2027

About 14% of large US employers have already dropped or plan to drop coverage of GLP-1 weight-loss drugs in 2027, according to the Business Group on Health's 2027 Large Employers Health Care Strategy Survey, conducted in June 2026 across 127 employers representing 11 million covered lives^[1]. That figure represents a meaningful reversal from the expansion that followed the 2021 FDA approval of semaglutide 2.4 mg for obesity and the 2023 approval of tirzepatide for the same indication. The retreat is driven by cost: pharmacy spending now accounts for 25% of total employer healthcare spend, and employers project a 12% pharmacy cost increase for 2026^[1].

What the survey data shows

The Business Group on Health reported that coverage of GLP-1 drugs for weight management fell from 72% of large employers in 2025 to 60% in 2026, and that 14% of survey participants have already dropped it or plan to do so by 2027^[1]. Two-thirds of those surveyed said GLP-1 drug usage among their employees had risen significantly. Overall healthcare cost trend is projected at a median 9.2% for 2027, with plan design changes expected to bring the effective increase to around 8%^[1]. Employers predicted a cumulative 76% cost increase over the decade from 2018 to 2027, roughly double general inflation.

Among employers that continue to cover GLP-1s for weight management, the 2027 survey found a shift toward tighter controls: 16% said they would redirect employees to direct-to-consumer channels for GLP-1 purchases, and 17% would pursue direct-to-employer purchasing arrangements to reduce unit cost^[1]. The pattern is cost management by eligibility gate rather than outright removal.

The KFF picture for smaller employers

The KFF 2025 Employer Health Benefits Survey, published in October 2025, captured a different slice of the market: firms of all sizes^[2]. Among firms with 200 to 999 workers, 16% covered GLP-1 agonists for weight loss. That figure rose to 30% for firms with 1,000 to 4,999 workers and 43% for firms with 5,000 or more employees (up from 28% the prior year). Crucially, among the largest employers covering these drugs, 59% reported usage was higher than expected and 66% said GLP-1s had a significant impact on their prescription drug spending.

Of large employers not yet covering GLP-1s for obesity, only 1% described themselves as very likely to add the benefit within the next 12 months, while 67% said it was not likely^[2]. That muted expansion appetite, combined with the active dropouts reported by the Business Group on Health, points to a market that has peaked in access rather than continuing to widen.

Why employers are cutting back

The list price of branded GLP-1 weight-loss drugs in the US is a structural problem for self-insured employers. Semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) carry list prices that run to around $1,000 to $1,400 per month per patient at commercial rates. Employers covering these drugs at scale see the cost compound across thousands of enrollees. A 2026 study in Obesity Science and Practice found that when employers removed GLP-1 coverage for obesity, employees reported significantly negative perceptions of their employer^[3], suggesting the coverage decision carries reputational consequences. Even so, the financial pressure is overriding that risk for a meaningful share of benefit managers.

The cost problem is not unique to GLP-1 drugs, but the scale is. No other drug category in commercial pharmacy history has combined a unit price above $1,000 per month with eligible-population estimates in the tens of millions. Obesity prevalence in the US is near 42% in adults; the drugs work at the population level. The tension between clinical evidence and benefit affordability is therefore acute in a way it has not been for other expensive drug categories, which typically target smaller or more clearly defined patient groups.

What patients lose when coverage drops

An employer removing GLP-1 coverage for obesity does not remove access, but it does remove affordability. Patients moving to out-of-pocket purchase face list prices that most cannot sustain. Manufacturer savings programmes (Lilly's Zepbound savings card, Novo Nordisk's Wegovy savings programme) reduce cost for commercially insured patients, but are generally unavailable to the uninsured or those on Medicare. The coverage gap lands hardest on lower-income workers within an employer's workforce, widening the income-related access disparity that already characterises GLP-1 uptake^[3].

The drugs involved are prescription-only in the United States. The semaglutide regulatory overview and the tirzepatide regulatory overview on this site cover FDA approval status, indicated uses, and prescribing conditions for both agents. Neither can be obtained without a valid prescription from a licensed US prescriber.

The compounding parallel

When branded GLP-1 drugs were in shortage between 2022 and 2024, the FDA allowed compounding pharmacies to produce semaglutide and tirzepatide. That pathway, always contested by the branded manufacturers, effectively closed when the FDA removed both drugs from the shortage list in 2025 and sent a wave of warning letters to compounders. Patients who had relied on lower-cost compounded versions found themselves facing brand-name prices just as employer coverage was beginning to narrow. The timing of both changes falling in the same window has tightened access from two directions at once.

What this does not tell us

The Business Group on Health survey represents large employers (127 firms, 11 million covered lives) and does not speak to smaller employers, Medicaid programmes, or Medicare Part D plans. The Inflation Reduction Act added Medicare coverage for anti-obesity medications starting in 2026 for Medicare Advantage plans, which partially offsets the large-employer retreat for the over-65 population. The net change in covered lives across all payer types is not yet clear. The survey also does not capture how many dropped-coverage employers will restore it if list prices fall following patent expiry or biosimilar entry, both of which are still several years away for semaglutide and further for tirzepatide.

The incretin class is still expanding: retatrutide posted a 28.3% mean weight loss at 80 weeks in TRIUMPH-1 in May 2026, oral GLP-1 options are entering commercial phase, and several pipeline agents are in late-stage trials. The evidence base for the class is strengthening at the same time the affordability architecture is narrowing. Whether those two trajectories converge depends on whether generic or biosimilar competition arrives, and on whether CMS pricing negotiations under the Inflation Reduction Act change the commercial price reference. For the period through 2027, the Business Group on Health data suggests access will contract in the employer channel before it expands again^[1].